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Abstract
Objectives
As trials were assessing the safety and efficacy of daily oral antiretroviral preexposure pro-
phylaxis (PrEP) for the prevention of HIV infection, there was a clear need to understand
the evolution of knowledge of, and attitudes toward, PrEP among primary care clinicians.
Methods
Physicians and nurse practitioners were surveyed in 2009 (n = 1500), 2010 (n = 1504),
2012 (n = 1503), 2013 (n = 1507), 2014 (n = 1508) and 2015 (n = 1501) to assess their
awareness of PrEP, willingness to prescribe PrEP, and whether they support use of public
funds to pay for PrEP. Pharmacists (n = 251) were surveyed about PrEP in 2012 only.
Descriptive statistics were computed for physician demographics and PrEP-related ques-
tions. Prevalence ratios for willingness to prescribe PrEP were computed using Poisson
regression analysis.
Results
Awareness of PrEP was low among clinicians (2009: 24%, 2010: 29%) but increased after
trials reported effectiveness (2012: 49%, 2013: 51%, 2014: 61%, 2015: 66%). Following a
description of PrEP with an estimated effectiveness of 75%, across 6 of the study years
91% of clinicians indicated a willingness to prescribe PrEP to at least one group at high risk
of HIV acquisition. A smaller majority of clinicians indicated support for public funding of
PrEP in 2009: 59%, 2010: 53%, and 2013: 63%.
Conclusions
In surveys conducted before and after the release of PrEP trial results, primary care clini-
cians were largely unaware of PrEP. They indicated high levels of willingness to prescribe it
for patients at high risk of HIV acquisition and expressed interest in education about how to
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deliver this new clinical HIV prevention method. It will be important to continue monitoring
clinician knowledge, attitudes, and practices as the use of PrEP increases in the US.
Introduction
In recent years, reductions in rates of new HIV infections in the United States (US) have stalled
at approximately 45,000 per year and in some groups (e.g., young men) annual HIV infections
are increasing [1]. In response to the need for additional effective prevention methods, clinical
trials were undertaken to test the safety and effectiveness of daily oral antiretroviral preexpo-
sure prophylaxis (PrEP). Between 2010 and 2014, these trials reported the effectiveness of daily
doses of tenofovir disoproxil fumarate (TDF) alone or in combination with emtricitabine
(FTC), in reducing HIV acquisition among gay, bisexual, and other men who have sex with
men (MSM) [2], persons who inject drugs (PWID) [3], and heterosexually-active men and
women (HET) [4,5].
In parallel to the start of efficacy trials, efforts began to understand how PrEP would best be
implemented in the US when and if safety and substantial efficacy were demonstrated. A few
studies were done to assess early levels of knowledge about, acceptability of, and use of PrEP in
selected US groups of MSM [6–9] and heterosexuals in care at sexually transmitted disease
(STD) clinics [10, 11]. However, few studies were done early on among the primary implemen-
ters of this new intervention, clinicians who would be called upon to identify their HIV-unin-
fected patients for whom PrEP would be most appropriate and to prescribe and manage a
course of PrEP medication with indicated counseling and safety monitoring [12–16]. These
early clinician studies were limited to a single geographic area, or to HIV or infectious disease
specialists.
We set out to assess the awareness of, and attitudes about, PrEP in a national sample of pri-
mary care clinicians in the US. Given the vigorous recent public conversations about health
care costs and the roles of public and private sector payers, we also assessed some attitudes
about the acceptability of public funding for PrEP.
Materials and Methods
Survey Methods
Porter Novelli Public Services conducts annual web-based surveys with a main sample of pri-
mary care physicians and additional samples of other selected specialties. In 2009, 2010, and
2012, respondents for the DocStyles surveys were drawn from the Epocrates opt-in, verified
panels of physicians (Honors Panel) and nurse-practitioners and registered dieticians (Allied
Health Panel). Verification was achieved by checking each physician's first name, last name,
date of birth, medical school, and graduation date against the American Medical Association’s
master file of physicians licensed in the United States at the time of panel registration. A ran-
dom sample of clinicians—drawn each year to match the American Medical Association's mas-
ter file proportions for age, sex, and region—were invited to participate in the survey.
Physicians, nurse practitioners, and registered dietitians were then screened for eligibility to
participate in the survey if they practiced in the United States; actively saw patients; worked in
an individual, group, or hospital practice; and had practiced medicine for at least 3 years. Phar-
macists were included in 2012 only and were required to be customer-facing, work in the
United States, and have been a pharmacist for at least three years. Quotas were set each year to
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reach 1,000 primary care physicians, 250 pediatricians, 250 OB/GYNs, 250 nurse practitioners,
200 registered dietitians, and in 2012 only, 250 retail pharmacists.
In 2014 and 2015, the clinician samples were drawn from SERMO’s Global Medical Panel
which includes over 330,000 healthcare professionals. Panelists were verified using a double
opt-in sign up process with telephone confirmation at place of work. Each year, SERMO took a
random sample of eligible healthcare professionals in the United States from their main data-
base to load into their invitation database.
In all survey years, pediatricians and registered dieticians were not asked about PrEP on the
DocStyles questionnaire and therefore are not included in our analysis sample. In 2009, the
only year they were included in DocStyles, dermatologists were excluded from PrEP questions
and the analysis sample.
Survey instruments were developed by Porter Novelli with technical guidance from its fed-
eral public health agencies, nonprofit, and for-profit clients. Some survey questions were not
asked in all survey years. In the first two survey years (2009, 2010), attitudes were assessed
based on a hypothetical PrEP effectiveness of 75% because these survey waves were conducted
prior to the publication of results from any of the PrEP effectiveness trials. In the three trials
that showed significant reductions in the risk of sexual acquisition of HIV infection among
those given PrEP [2, 4, 5], the prevention effectiveness shown for trial participants with high
self-reported adherence (73–78%) was very similar to the estimate provided to the DocStyles
survey respondents (75%). This estimate was especially appropriate given that, in clinical prac-
tice, medication adherence is most commonly assessed by patient self-report. Based on addi-
tional data about the effectiveness of PrEP among those with drug detected indicating
adherence to daily doses, the data presented in the survey was more nuanced. In 2012 and
2013, the estimated effectiveness provided to respondents was “90% or more among those who
took it nearly every day” and less if adherence was poor (2012; 0–50%, 2013; 20–50%).
The Centers for Disease Control and Prevention (CDC) licenses access to results of the Doc-
Styles surveys post-collection from Porter Novelli. Analysis of these data was exempt from
CDC institutional review board approval because personal identifiers were not included in the
data files received for analysis.
Analysis Methods
Prevalence ratios were computed to determine the strength of association between clinicians
willing to prescribe PrEP to at least one high risk group (PWID, MSM, persons with an STD,
people who change sex partners frequently, HIV discordant couples, HIV discordant couples
attempting to conceive) and each of eight clinician characteristics (age, sex, race/ethnicity, cli-
nician specialty, clinician work setting, number of clinicians in practice, number of years in
practice, having provided antiretrovirals for postexposure prophylaxis (PEP) or treatment of
HIV infection).
Univariate prevalence ratios measured the association between the outcome and each of the
eight characteristics. Multivariable prevalence ratios measured the association between the out-
come and each of the eight characteristics adjusting for the effects of all other characteristics in
a multiple regression model.
Generalized estimating equations using a robust variance estimator and assuming a Poisson
model with an independent working correlation matrix was used to analyze the effect of time
(measured in years) on the proportions of clinicians who have heard of PrEP, who are willing
to prescribe PrEP to at least one high risk group, and to each high risk group. High risk groups
identified were PWID, MSM, persons with a sexually transmitted disease, people who change
sex partners frequently, HIV discordant couples not intending conception, and HIV discordant
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couples attempting to conceive. All eight characteristics and each of their interactions with
year were considered in adjusted linear trend analyses. Both forward selection and backward
elimination were used to determine the factors that were controlled for in each model.
Only those characteristics and those interactions that were significant at the 0.05 level were
kept in the final models.
Results and Discussion
For the 2009 survey, of the 2,825 eligible physicians (excluding dermatologists and pediatri-
cians) invited, 1,250 (44%) physicians completed the entire survey. Of 500 eligible nurse-practi-
tioners invited, 250 completed the entire survey (response rate 50%). For the 2010 survey, of
the 2,308 eligible physicians invited (excluding pediatricians), 1,250 (54%) completed the entire
survey. Of 431 eligible nurse-practitioners invited, 254 (59%) completed the entire survey. For
the 2012 survey, of the 2,664 eligible physicians invited (excluding pediatricians), 1,251 (34%)
completed the entire survey. Of 456 eligible nurse-practitioners invited, 252 (55%) completed
the survey. For the 2013 survey, of the 1,802 eligible clinicians invited, 1,257 (70%) completed
the survey. Of the 450 eligible nurse practitioners invited, 250 (55%) completed the survey. For
the 2014 survey, of the 1717 eligible clinicians invited, 1258 (73%) completed the survey. Of
the 398 eligible nurse practitioners invited, 250 (63%) completed the survey. For the 2015 sur-
vey, of the 1,794 eligible clinicians invited, 1,500 (84%) completed the survey. Of the 481 eligi-
ble nurse practitioners invited, 251 (40%) completed the survey.
Demographic and Practice Characteristics of Responding Clinicians
The majority of clinicians were male (61%), white (70%), and worked in a group practice
(66%) (Tables 1 and 2). Family practitioners/general practitioners (36%) and internists (31%)
constituted the largest groups of respondents, followed by nurse practitioners (17%) and obste-
trician/gynecologists (17%). Among clinicians, 66% believed the population served by their
practice was low prevalence for HIV (<1%); 16% believed it to be a moderate prevalence popu-
lation (1–5%) and 3% a high prevalence population (>5%). Furthermore, 15% responded they
did not know the level of HIV infection in their practice community.
HIV Testing Practices
Routine screening for HIV infection was reported by 35% of clinicians for all sexually active
adults not previously tested and by 20% for all patients (ages 13–64) not previously tested.
Most (81%) clinicians reported providing HIV testing when requested by a patient. Condition
or population-specific routine HIV testing was reported by 74% of clinicians for patients seek-
ing treatment for an STD, by 55% for all pregnant women, by 52% for all MSM, and by 36% for
all patients initiating treatment for tuberculosis. A minority (9%) do not offer routine HIV
screening for any group of patients.
Table 1. Clinician Characteristics, DocStyles, 2009–2015, United States. Total Sample Size (2009–
2015) N = 9023.
Characteristic Median value Range
Age (years) 46 22–95
Number of Clinicians in Practice 5 1–999
Number of Years in Practice 14 3–50
doi:10.1371/journal.pone.0156592.t001
PrEP DocStyles Survey 2009–2015
PLOS ONE | DOI:10.1371/journal.pone.0156592 June 3, 2016 4 / 12
Antiretroviral Prescribing
In 2012 and 2013, an average of 26% of clinicians responded that they had prescribed antiretro-
viral medication for treatment of HIV infection; among these clinicians, 44% reported provid-
ing treatment for 1–4 HIV-infected patients, 24% for 5–9 patients, 18% for 10–24 patients, and
15% for 25 or more patients.
Across six survey years (2009, 2010, 2012, 2013, 2014, 2015), 24% reported having pre-
scribed antiretroviral medication for occupational postexposure prophylaxis (PEP) and 10%
had prescribed it for nonoccupational PEP. In 2009, 2010, and 2012, few clinicians (1%)
reported having prescribed PrEP. The proportion reporting having prescribed PrEP rose to 4%
in 2013, remained 4% in 2014, and rose to 7% in 2015. In 2015, of those who had prescribed
PrEP, 73% had done so for MSM, 22% for PWID, 22% for uninfected men and 27% for unin-
fected women in HIV discordant couples during conception attempts, 45% for uninfected
women in an HIV discordant couple not planning conception and 30% for uninfected men in
this situation.
Awareness and Attitudes About PrEP
Awareness of PrEP was low in 2009 (24%) and 2010 (29%) but increased to 49% in 2012, 51%
in 2013, 61% in 2014, and 66% in 2015 (adjusted p-value of<0.001). In 2013, few reported hav-
ing read CDC interim guidance for PrEP use with MSM (8%), heterosexually active adults
(10%) or PWID (10%). However, in 2014, 17% reported having read the CDC’s PrEP clinical
practice guidelines published in May of that year.
Table 2. Clinician Sample Characteristics, DocStyles, 2009–2015, United States. Total Sample Size
(2009–2015) N = 9023.
Clinician Sample Characteristics %
Sex
Male 60.9
Female 39.1
Race/Ethnicity
White 69.7
Black/African American 3.2
Hispanic/Latino 4.2
Asian 17.6
Other 5.4
Specialty
Family Practice/General Practitioner 36.1
Internist 30.6
Obstetrician/Gynecologist 16.6
Nurse Practitioner 16.7
Work Setting
Hospital Inpatient Practice 13.9
Group Outpatient Practice 66.4
Individual Outpatient Practice 19.7
Region (2012–2015 only)
Midwest 22.9
Northeast 25.4
South 30.2
West 21.4
doi:10.1371/journal.pone.0156592.t002
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Across five survey years (2009, 2010, 2012, 2013, 2015), the majority of clinicians supported
PrEP use for one or more risk populations presented (91%). Clinicians’ willingness to provide
PrEP was highest for the uninfected partner in an HIV discordant couple (79%), followed by
MSM (66%) and PWID (63%), those in HIV discordant couples planning conception (61%),
persons who change sexual partners frequently (56%), and persons with a diagnosed STD
(34%).
Willingness to prescribe for at least one high risk group or for discordant couples trying to
conceive and having heard of PrEP increased (all p-values<0.0001). Willingness to prescribe
PrEP for MSM, PWID, persons who change partners frequently and for discordant couples not
trying to conceive remained stable (p-values>0.5) but decreased for persons with an STD (p-
value<0.004) and differed by primary care provider type (Figs 1 and 2).
Across the survey years 2009, 2010, and 2013, 58% of clinicians supported the use of state or
federal government funds to provide PrEP for uninsured persons.
Predictors of Willingness to Prescribe PrEP
In a multivariable association analysis, only five clinician factors were modestly predictive of
willingness to prescribe PrEP to one or more risk populations (Table 3). Obstetrician/gynecolo-
gists were slightly more willing than family physicians, as were those clinicians in a group prac-
tice, compared to a solo practice. Clinicians in larger practices (>20 providers) were slightly
less willing to prescribe PrEP than those in small practices (<5 providers), as were clinicians
Fig 1. Awareness of PrEP andWillingness to Prescribe PrEP to Persons with Selected Risks for HIV
Acquisition by Survey Year, DocStyles, 2009–2015, United States.
doi:10.1371/journal.pone.0156592.g001
Fig 2. Awareness of PrEP andWillingness to Prescribe PrEP to Persons with Selected Risks for HIV
Acquisition by Provider Type, DocStyles, 2009–2015, United States.
doi:10.1371/journal.pone.0156592.g002
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45–54 years of age compared to those 55 years of age or older. Gender, race/ethnicity, and
number of years in practice were not predictive. Having provided antiretrovirals for postexpo-
sure prophylaxis or for treatment of HIV infection was also predictive of willingness to pre-
scribe PrEP. In a multivariable trend analysis, three physician characteristics, having provided
Table 3. Association of Clinician Characteristics with Willingness to Prescribe PrEP: DocStyles 2009–2015, United States.
Characteristic No. (%) Univariate Prevalence Ratio (95% CI) Multivariate Prevalence Ratio (95% CI)
Age (years)
55 1708 (92.03) Referent Group Referent Group
45–54 2013 (90.43) 0.98 (0.96, 1.00) 0.98 (0.96, 1.00)*†
35–44 2476 (90.46) 0.98 (0.97, 1.00) 0.98 (0.95, 1.01)
20–34 647 (92.96) 1.01 (0.99, 1.04) 1.01 (0.97, 1.05)
Gender
Male 4137 (90.51) Referent Group Referent Group
Female 2707 (91.95) 1.02 (1.00, 1.03)* 1.02 (1.00, 1.03)
Race/Ethnicity
White 4849 (90.98) Referent Group Referent Group
Black 229 (92.71) 1.02 (0.98, 1.06) 1.01 (0.98, 1.05)
Hispanic 274 (89.25) 0.98 (0.94, 1.02) 0.98 (0.94, 1.02)
Asian 1153 (92.02) 1.01 (0.99, 1.03) 1.02 (1.00, 1.04)
Other 339 (89.68) 0.99 (0.95, 1.02) 0.99 (0.96, 1.03)
Clinician Specialty
Family/General Practitioner 2473 (91.05) Referent Group Referent Group
Internist 2055 (89.70) 0.99 (0.97, 1.00) 0.98 (0.96, 1.00)
Obstetrician/Gynecologist 1169 (93.45) 1.03 (1.01, 1.05)* 1.04 (1.02, 1.06)*
Nurse Practitioner 1147 (91.25) 1.00 (0.98, 1.02) 1.00 (0.98, 1.02)
Clinician Work Setting
Individual Outpatient Practice 1321 (90.05) Referent Group Referent Group
Group Outpatient Practice 4552 (91.44) 1.02 (1.00, 1.04) 1.02 (1.00, 1.04)
Hospital Inpatient Practice 971 (90.75) 1.01 (0.98, 1.03) 1.02 (0.99, 1.05)
Number of Clinicians in Practice
5 3666 (91.28) Referent Group Referent Group
6–19 2054 (91.70) 1.00 (0.99, 1.02) 1.00 (0.98, 1.01)
20 1124 (89.28) 0.98 (0.96, 1.00)*† 0.97 (0.95, 0.99)*
Number Years in Practice
>20 1937 (91.45) Referent Group Referent Group
11–20 2490 (90.84) 0.99 (0.98, 1.01) 1.00 (0.97, 1.02)
6–10 1723 (90.64) 0.99 (0.97, 1.01) 0.99 (0.97, 1.02)
0–5 694 (91.92) 1.01 (0.98, 1.03) 1.00 (0.97, 1.04)
Prescribed nPEP, oPEP, ARTs
No 4467 (89.20) Referent Group Referent Group
Yes 2377 (94.81) 1.06 (1.05, 1.08)* 1.07 (1.06, 1.09)*
CI: Conﬁdence Interval; No.: number of Yes respondents for the indicated characteristic.
* Conﬁdence intervals indicate a statistically signiﬁcant association at the 0.05 signiﬁcance level.
† Some CIs that do not but might appear to include 1.0 as a result of rounding
Note: Univariate analyses test the association between the indicated characteristic and prescribing for at least one high risk group; multivariate analyses
show the association between the indicated characteristic and prescribing for at least one high risk group while adjusting for all other characteristics listed
in the table; Pediatricians were not solicited to respond to this question.
doi:10.1371/journal.pone.0156592.t003
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antiretrovirals for postexposure prophylaxis or for treatment of HIV infection, age, and the
interaction of age with years in practice were predictive of an increase in willingness to pre-
scribe PrEP (adjusted p-value of<0.001).
PrEP Implementation Factors
Eight to ten percent had read one or more of the interim guidance documents issued by CDC
published in 2011, 2012, and 2013. However, in 2014, 17% had read the final clinical practice
guidelines increasing to 22% in 2015. Clinicians most commonly reported that formal CDC or
PHS guidelines (52%) would have the greatest influence about prescribing PrEP, followed by a
US Preventive Services Task Force recommendation (19%) or a recommendation from their
specialty professional association (15%). Few would be guided primarily by American Medical
Association or National Medical Association clinical practice statements (6%), state or local
public health department guidance (5%), or a practice statement from their clinical organiza-
tion (3%).
In response to several PrEP knowledge true/false questions presented on the surveys in
2012, 2013, and 2015, clinicians reported limited knowledge. For four of the questions the
most common answer was “don’t know” (64–68%). Incorrect response rates were greater than
correct responses for 2 questions: Atripla is recommended, safe and effective for PrEP (22%
true v 11% false) and follow-up HIV testing should be done at least once a year for those on
PrEP (58% true vs 5% false). Correct response rates were greater than incorrect responses for 4
questions: heterosexuals do not need hepatitis B screening before starting PrEP (8% true v 57%
false, asked in 2013 and 2015), a negative HIV test result should be documented before pre-
scribing PrEP (55% true vs 10% false), PrEP with Truvada is indicated during pregnancy for an
uninfected woman with an HIV-infected sexual partner (25% true vs 7% false), and PrEP is
safe and effective when taken just before and after sex instead of daily (26% false vs 11% true).
In 2015, of 1501 respondents, 3 clinicians answered all questions incorrectly and 5 clinicians
answered all questions correctly.
Most clinicians (83%) expressed interest in participating in online CME training on one of
more of the following topics: screening and selecting patients for PrEP (73%), managing side
effects and monitoring for adverse events (59%), brief risk-reduction counseling (57%), brief
medication adherence counseling (53%), taking a brief sexual history (49%), and billing for
PrEP-related services (48%).
When asked how they would provide recommended risk-reduction counseling to PrEP
patients if it were reimbursable, 37% would do the counseling themselves, 19% would have a
health education or other staff member provide the counseling, 17% would send the patient to
a dedicated counseling site in their clinic system, and 17% would refer for counseling in the
community. A majority of clinicians (59%) felt that counseling should be reimbursed at $50-
$100 while 22% felt that $101–200 was appropriate.
Pharmacy Services
In the 2012 survey only, pharmacists were asked about pharmacy services that could be used
for PrEP medication dispensing and other potential PrEP-related support. Among these phar-
macists, 66% reported that they currently provide reimbursable medication therapy manage-
ment (MTM) services, 43% that they currently provide some services under a collaborative
practice agreement, and 57% that they would be interested in providing on-site HIV testing for
pharmacy clients.
This is the first multi-year survey to assess knowledge and attitudes about PrEP among
large national samples of primary care clinicians in the US. In the DocStyles survey waves
PrEP DocStyles Survey 2009–2015
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conducted in 2009 and 2010, prior to publication of the results of the first trial documenting its
effectiveness and safety [2], awareness of PrEP was low among primary care clinicians. In the
years after trial results were published, awareness rose substantially.
The patient population for whom PrEP is indicated, i.e., persons without HIV infection, are
not usually receiving health care from infectious disease or HIV treatment specialists. They
often may not wish to seek health care in HIV treatment clinics because of a concern that, if
seen there by persons who know them, they will be thought to have HIV-infection. Primary
care clinicians providing general health care for persons without HIV infection may therefore
play a significant role in PrEP delivery [17].
A qualitative study of HIV care providers proposed a “purview paradox” in which HIV spe-
cialists thought primary care providers were best positioned to provide PrEP, but HIV care
providers were most capable to do it [18]. However, a recent study that included convenience
samples of both HIV and non-HIV providers attending HIV conferences in California and
New York, each type of provider (HIV, non-HIV) felt that they were best suited to provide
PrEP. This study also reported that HIV providers had more knowledge about PrEP and that
knowledge was a strong predictor of future intent to prescribe PrEP [19]. An earlier study of
STD and family planning clinic providers also found higher willingness to provide PrEP
among clinicians with higher knowledge scores [20]. In the DocStyles survey, clinicians
reported low exposure to any of the CDC interim guidance issued in 2011–2013 [21–23] (8–
10%) and limited knowledge of PrEP on true false questions with high rates of “don’t know” as
a response and very few answering all 5 questions correctly. Clinicians were aware of their
knowledge deficits and indicated substantial interest in CME for all topics presented. They also
indicated they would be influenced by formal CDC/PHS guidelines. These were issued in May
2014 [24].
In all DocStyles survey years, both primary care clinicians initially aware of PrEP and those
initially unaware but provided with information about it, reported high levels of willingness to
prescribe PrEP to at least one subgroup of persons at substantial risk for HIV acquisition. In
addition, support for public funding of PrEP for those who could not otherwise afford it was
consistently high among clinicians across survey years.
There are limitations to this study. While the effectiveness described on the surveys ranged
from 75% in 2009 and 2010 to ~90% among adherent users in 2012–2015, the high and stable
estimated willingness to prescribe PrEP reported across the five waves of the survey when this
was assessed may or may not be a realistic approximation of primary care clinicians’ attitudes
in the US in this early phase of introducing PrEP as a clinical HIV prevention method.
While DocStyles is a large, national survey that includes a diverse group of primary care cli-
nicians, it is not a fully representative survey sample. However, the selection of invited partici-
pants using quota sampling has been found to include participants that were demographically
comparable (gender, age, average years in practice) with physicians in the AMAMasterfile
(unpublished data, Porter Novelli, DocStyles 2009 Methods, Washington DC, 2009).
Additional limitations are the change in sampling frame that occurred between the 2010
and 2012 surveys and the small amount of information available about the patient populations
served by the respondents. We did not assess the proportion of the respondent’s patients who
have risk factors that are potential indications for PrEP, e.g., MSM, PWID, persons in HIV-dis-
cordant sexual partnerships, or sexually active persons with frequent bacterial STIs diagnosed.
It is critical that primary care providers with such patients are knowledgeable about and
willing to prescribe PrEP. A recent qualitative study found that clinical and non-clinical pro-
viders in substance abuse treatment centers in New York City had limited awareness of PrEP’s
effectiveness for PWID [3] (11% of respondents) but when it was explained to them, identified
challenges to incorporating it into their services, as well as receptivity to learning about its
PrEP DocStyles Survey 2009–2015
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delivery to clients they identified as likely to benefit from it [25]. A recent survey of women’s
health clinicians attending a regional HIV conference found that 66–72% (depending on the
sex of the uninfected partners) had discussed PrEP with an HIV-discordant couple interested
in pregnancy conception [26]. For primary care clinicians to successfully incorporate PrEP
into their practices, it will be important to learn applicable lessons from adoption of other pre-
ventive innovations in clinical settings [27]. This should include attention to factors affecting
both their commitment (e.g., awareness, anticipated perceptions, role congruence) and their
perceived capacity (e.g., service delivery congruence, role support, skills efficacy) to introduce a
new method.
Conclusions
As PrEP is introduced into clinical practice and its availability is scaled-up, it will be important
to continue to monitor clinician knowledge, attitudes, and practices for PrEP and other clini-
cally-delivered HIV prevention interventions. This will facilitate creating materials and meth-
ods for both providers and their patients that will increase awareness of PrEP and its
prescription when indicated with effective support for the medication adherence necessary to
achieve significant reductions in the risk of HIV acquisition.
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